移至標頭
移至導覽
移至內部
移至註腳
登入
幫助
English
研究資源
CUHK UPDates
論文庫
專家名錄
使用指引
關於我們
研究人員名單
> Professor Lai Shan TAM
主頁
研究成果
研究人員專頁
學系學部專頁
研究範圍
譚麗珊教授
個人資料
職位/學系
教授
,
內科及藥物治療學系
ORCiD
0000-0001-6410-8852
中大研究成果
1/10
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
(
2024
)
DCES-PA: Deformation-controllable elastic shape model for 3D bone proliferation analysis using hand HR-pQCT images
(
2024
)
Impact of inflammation and anti-inflammatory therapies on the incidence of major cardiovascular events in patients with ankylosing spondylitis: a population-based study
(
2024
)
Incidence and risk factors of major cardiovascular events in rheumatoid arthritis and psoriatic arthritis: A population-based cohort study
(
2024
)
Moderate and high disease activity levels increase the risk of subclinical atherosclerosis progression in early rheumatoid arthritis: a 5-year prospective study
(
2024
)
OMERACT 2023 Systemic Lupus Erythematosus Special Interest Group: Winnowing and Binning Preliminary Candidate Domains for the Core Outcome Set
(
2024
)
A novel visceral adiposity index predicts bone loss in female early rheumatoid arthritis patients detected by HR-pQCT
(
2023
)
Automatic 3D joint erosion detection for the diagnosis and monitoring of rheumatoid arthritis using hand HR-pQCT images
(
2023
)
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis
(
2023
)
Erosion Identification in Metacarpophalangeal Joints in Rheumatoid Arthritis using High-Resolution Peripheral Quantitative Computed Tomography
(
2023
)
Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: a case-control study
(
2023
)
Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
(
2023
)
Global, regional, and national trends in incidence of asthma: findings from the Global Burden of Disease Study 2019
(
2023
)
Global, regional, and national trends in incidence of asthma: findings from the Global Burden of Disease Study 2019
(
2023
)
Global, regional, and national trends in incidence of inflammatory bowel disease: findings from the global burden of disease study 2019
(
2023
)
Inflammation is associated with incident hypertension in patients with axial spondyloarthritis: A longitudinal cohort study
(
2023
)
Risk of alanine aminotransferase flare in patients with previous hepatitis B virus exposure on biological modifier therapies-A population-based study
(
2023
)
Role of Inflammatory Burden and Treatment on Joint Space Width in Psoriatic Arthritis - a High-Resolution Peripheral Quantitative Computed Tomography Study
(
2023
)
Telemedicine for follow-up of systemic lupus erythematosus during the 2019 coronavirus pandemic: A pragmatic randomized controlled trial
(
2023
)
The impact of comorbidities in patients with spondyloarthritis
(
2023
)
The temporal trend of disease burden attributable to metabolic risk factors in China, 1990–2019: An analysis of the Global Burden of Disease study
(
2023
)
Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study
(
2023
)
Urinary Long Non-Coding RNA Levels as Biomarkers of Lupus Nephritis
(
2023
)
Are We Treating-to-target in Spondyloarthritis (SpA)? A Cross Sectional Analysis from the Asia Pacific League of Associations for Rheumatology (APLAR) SpA Registry
(
2022
)
Are we treating-to-target in spondyloarthritis (SpA)? A cross sectional analysis from the Asia Pacific League of Associations for Rheumatology (APLAR) SpA Registry
(
2022
)
Bone Microarchitecture Assessed by High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Predicts Fracture Risk in Patients with Rheumatic Diseases on Glucocorticoids
(
2022
)
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
(
2022
)
Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Updates to a Systematic Literature Review and Network Meta-Analysis
(
2022
)
Comparative Profiling of Serum Protein Biomarkers and Disease Activity Across Various Disease Domains in Patients with Psoriatic Arthritis (PsA)
(
2022
)
Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ by Braun and Landewé
(
2022
)
Domains Contributing to Minimal Disease Activity Achievement in Patients with Psoriatic Arthritis Receiving Guselkumab
(
2022
)
Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
(
2022
)
Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
(
2022
)
Early Clinical Improvement as Predictor of Long-term Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Guselkumab: Post Hoc Analysis Through 2 Years of a Phase 3 Study
(
2022
)
Early Clinical Improvement as Predictor of Long-term Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Guselkumab: Post Hoc Analysis Through 2 Years of a Phase 3 Study
(
2022
)
Effect of Upadacitinib on Bone Erosion Repair in Rheumatoid Arthritis: A Pilot Study
(
2022
)
Efficacy and Safety of Guselkumab in Biologic-Naïve Patients With Active Axial Psoriatic Arthritis: Study Design of a Phase 4, Randomized, Double-Blind, Placebo-Controlled Trial
(
2022
)
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
(
2022
)
Five-Year Cardiovascular Event Risk in Early Rheumatoid Arthritis Patients Who Received Treat-to-Target Management
(
2022
)
Five-Year Cardiovascular Event Risk in Early Rheumatoid Arthritis Patients Who Received Treat-to-Target Management
(
2022
)
Guselkumab Provides Consistent and Durable Pain Improvement in Patients with Active Psoriatic Arthritis: Results of 2 Phase 3, Randomized, Controlled Clinical Trials
(
2022
)
High Inflammatory Burden Predicts Cardiovascular Events in Patients with Axial Spondyloarthritis: A Long-Term Follow-Up Study
(
2022
)
High inflammatory burden predicts cardiovascular events in patients with axial spondyloarthritis: a long-term follow-up study
(
2022
)
Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus
(
2022
)
Immunogenicity and Safety of Inactivated and Mrna Covid-19 Vaccines in Patients with Systemic Lupus Erythematosus
(
2022
)
Inflammation Is Associated with Incident Hypertension in Patients with Axial Spondyloarthritis: A Longitudinal Cohort Study
(
2022
)
Inflammation is Associated with Incident Hypertension in Patients with Axial Spondyloarthritis: A Long-Term Follow-Up Study
(
2022
)
Jagged Ends on Multinucleosomal Cell-Free DNA Serve as a Biomarker for Nuclease Activity and Systemic Lupus Erythematosus
(
2022
)
Nonsteroidal anti-inflammatory drugs and cardiovascular disease risk in spondyloarthritis-spectrum diseases
(
2022
)
Performance of the 2017 European Alliance of Associations for Rheumatology/American College of Rheumatology classification criteria in Patients With Idiopathic Inflammatory Myopathy and Anti–Melanoma Differentiation–Associated Protein 5 Positivity
(
2022
)
Most Relevant Area
Others
(
Internal medicine related
)
Related Area
Cardiovascular medicine and surgery
(
Internal medicine related
)
Medical imaging
(
Surgical and related
)
分享連結
上次更新時間 2024-03-09 於 16:09
分享連結
您的名稱*
您的電子郵件*
收件者名稱*
收件者電子郵件*
訊息
Auxilliary Information
不會儲存任何資訊或與任何第三方分享資訊。
Cancel
Our policy towards the use of cookies
All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Ok to Continue
Cookie Policy
